Skip to main content
Psychedex

Cannabis

Overview

Cannabis (Cannabis sativa L., Cannabaceae) — weed, pot, marijuana — is a flowering plant whose resinous preparations are among the most widely consumed psychoactive substances on earth.[1] Its primary psychoactive constituent, tetrahydrocannabinol (tetrahydrocannabinol), is chemically distinct from classical opioids or serotonergic psychedelics. THC activates the brain's endocannabinoid system, disrupting normal signaling across memory, reward, and sensory processing circuits.[2]

Cannabis (Cannabis sativa L., Cannabaceae) — weed, pot, marijuana — is the most widely consumed illicit psychoactive plant worldwide, whose resinous preparations produce intoxication through a family of terpenophenolic compounds called phytocannabinoids.[1] Its primary psychoactive constituent, tetrahydrocannabinol (Δ9-tetrahydrocannabinol), is a partial CB₁ receptor agonist structurally distinct from classical opioids or serotonergic psychedelics. THC produces its principal effects by activating CB₁ receptors in the brain, disrupting retrograde synaptic signalling across the hippocampus, basal ganglia, and prefrontal cortex.[2]

Entity
Cannabis
NoticeAll →
•11 dangerous interactions(all →)
FamilyCannabaceae
GenusCannabis
SpeciesCannabis sativa L.
Native rangeCentral Asia to Xinjiang (northwestern China) and Pakistan; centre of domestication in East Asia
CultivationBoth wild (feral landraces) and extensively cultivated globally across six continents in temperate and subtropical zones. Dioecious annual herb. Major cultivated regions include Afghanistan, China, Netherlands, Canada, United States, Morocco, India.
→ THC1–30 %
→ CBD0.1–20 %
→ CBG0–1 %
Flower (smoked)Flower (vaporised)Edible (oral)Oromucosal spray (nabiximols)
PsychoactiveCannabinoid
ChemicalCannabinoid
+1 moreTerpenoid
threshold1–2 mg
common5–15 mg
heavy25+ mg
15–30% THC in commercial drug-type cultivars; bioavailability 10–35%
Doses in mg of THC delivered. Onset seconds to 2 minutes; peak 5–15 minutes; duration 1–4 hours. Dose tiers synthesised from multiple clinical studies — not from a single dose-finding trial. FLAG: requires human editor review.
threshold1–2 mg
common5–15 mg
heavy25+ mg
15–30% THC in commercial drug-type cultivars; bioavailability comparable to smoking
Doses in mg of THC delivered. Heated to 170–210°C without combustion. Onset, peak, and duration mirror smoked flower. Avoids combustion byproducts. Zuurman et al. (2008) administered 2, 4, 6, and 8 mg pure THC via Volcano vaporizer with dose-dependent effects.
common5–10 mg
Variable; standard regulated serving is 10 mg THC per unit; bioavailability 4–12%
Doses in mg of THC ingested. First-pass metabolism produces 11-OH-THC (active metabolite that crosses BBB more efficiently). Onset 30 min to 2+ hours; peak 2–4 hours; duration 4–8 hours. Delayed onset frequently leads to unintentional overconsumption. FLAG: No published controlled dose-finding study provides definitive dose tiers for naive oral users.
common2.7–32.4 mg
2.7 mg THC + 2.5 mg CBD per actuation
Standardised pharmaceutical preparation (Sativex). Dose range represents 1–12 actuations/day as used in clinical trials. Partially bypasses first-pass metabolism; PK intermediate between inhalation and oral.
minlowmodhigh
Acute
Chronic
Physical
Psych.
Withdrawal
Buildupmoderate
Full reset17.5 days
Cross-tol.Synthetic cannabinoids, Other plant-derived CB1 agonists
Absolute1 entries
Pregnancy
Relative8 entries
Significant cardiovascular diseaseRespiratory disease (smoked preparations)Personal or family history of psychotic disordersHepatic impairmentAdolescence (under 25)Concurrent CYP2C9 substrates (e.g., warfarin)Concurrent CYP3A4 substrates (e.g., midazolam)Concurrent CNS depressants (opioids, benzodiazepines, alcohol)
danger11
GHB, BaclofenGHB, GBLIbogaineKetamine, DXM, PCP
caution33
Dosage varies by body weight, tolerance & metabolism · Not medical advice · Terms
See an error? Suggest correction
See an error? Suggest correction

Cannabis was domesticated in East Asia during the early Neolithic, spreading across Central and South Asia over millennia.[3] Raphael Mechoulam identified the structure of THC in the 1960s, launching modern cannabinoid science. Today cannabis is legally available for adult recreational use in Canada, Germany, and over 25 US states, while remaining federally prohibited in the United States.

Subjective effects include euphoria, heightened sensory perception, appetite stimulation, altered time perception, and relaxation.[4] Smoked preparations act within minutes and last one to three hours; edibles take 30–90 minutes to peak and can last four to eight hours, with a more sedating and body-prominent character. Anxiety, paranoia, and confused thinking emerge at higher doses or in susceptible individuals.[4]

Cannabis use disorder develops in approximately 9% of users, though no human fatality from cannabis alone has been documented.[5] The main ongoing risks are psychological dependence with a recognised withdrawal,[6] cyclic vomiting in heavy users,[7] and dose-dependent psychosis risk that increases with high-potency preparations.[8] Cannabis is among the more extensively studied psychoactive plants, but clinical evidence is largely absent for high-potency concentrates.

History[edit]

Traditional and historical use

Cannabis is among the oldest cultivated plants. Genomic evidence places domestication in East Asia during the early Neolithic,[3] with cannabis fibre in pottery dating to approximately 10,000 BCE in present-day Taiwan.[9] In India, preparations including bhang, ganja, and charas appear in ritual and medical records from the Vedic period.[10] Traditional use is historical fact, not evidence of therapeutic safety or efficacy.

Western discovery and research

William B. O'Shaughnessy brought cannabis to European medical practice in 1839.[10] Raphael Mechoulam isolated Δ9-THC in the 1960s, launching modern cannabinoid science.[10] The CB1 was identified in 1988 and localised in brain tissue,[11] followed by the endocannabinoid anandamide in 1992.[12]

Modern era

Cannabis was placed in Schedule I of the US Controlled Substances Act in 1970.[13] California legalised medical use in 1996; Canada legalised adult recreational use nationally in 2018.[14] Germany followed with partial legalisation in 2024,[15] and as of 2026 the US Department of Justice has initiated rescheduling of medical cannabis from Schedule I to Schedule III.[13]

Botanical Overview[edit]

The genus Cannabis contains a single accepted species: Cannabis sativa L. (family Cannabaceae).[16] The familiar retail labels "sativa" and "indica" do not correspond reliably to botanical taxonomy — generations of hybridisation have blurred any meaningful genetic distinction.[17] Three chemotypes are recognised: Type I (THC-dominant, 15–30%+ THC), Type II (balanced THC and CBD), and Type III (CBD-dominant, legally classified as hemp in most jurisdictions).[17]

Cannabis is native to Central and East Asia, with genomic analysis confirming East Asia as the centre of domestication.[3] It is now cultivated across six continents in temperate and subtropical climates.

The plant is an annual herb, typically producing male and female flowers on separate plants. Cannabinoids concentrate in the glandular trichomes of female flower clusters — not in seeds, roots, or fan leaves.[1] Hemp and high-THC drug-type cannabis are visually indistinguishable without chemical analysis.

Alkaloid Profile[edit]

Cannabis produces over 100 phytocannabinoids alongside hundreds of terpenes and flavonoids.[18][1] These exist primarily as inactive acid forms (THCA, CBDA) in the raw plant; heat from smoking, vaporising, or cooking converts them to their active forms.[19]

THC is the primary psychoactive constituent, activating cannabinoid receptors in the brain.[18][20] THC content ranges from under 1% in hemp to over 30% in high-potency cultivars; concentrates reach 50–90%+.[21] Cannabidiol (cannabidiol) is non-intoxicating — it partially dampens CB1 activity and activates serotonin receptors,[18][22] though at typical commercial ratios it does not significantly reduce THC's acute effects.[4]

Minor cannabinoids include CBG (the biosynthetic precursor to THC and CBD),[23] CBC (non-intoxicating, with preclinical anti-inflammatory properties),[23] CBN (a THC breakdown product in aged cannabis with mild sedative effects),[23] and THCV (which may suppress appetite at low doses).[20] Cannabis terpenes including β-myrcene, D-limonene, and β-caryophyllene also act at cannabinoid receptors,[24] and D-limonene selectively reduced THC-induced anxiety in a controlled study.[24] Potency varies significantly across cultivars and harvest batches; commercial labels may deviate ±15% or more from actual THC content.[25][26]

Neuroscience[edit]

Where it acts

THC hijacks the endocannabinoid system — a signaling network that normally uses lipid messengers to briefly slow neurotransmitter release at synapses.[12] By activating CB1 receptors continuously, THC disrupts the release of glutamate, GABA, dopamine, and acetylcholine across regions including the hippocampus (memory), prefrontal cortex (executive function), basal ganglia (reward and movement), cerebellum (coordination), and amygdala (emotion).[2][11] This explains the signature effects: impaired short-term memory, altered executive processing, euphoria, motor clumsiness, and shifting anxiety.

What it changes

With repeated exposure, CB1 receptors reduce in number and become less responsive, driving tolerance.[27] When cannabis is eaten rather than smoked, first-pass metabolism in the liver converts THC to 11-OH-THC — a compound that crosses the blood-brain barrier more efficiently and likely explains why edibles feel more intense and longer-lasting.[28]

Subjective Effects[edit]

Summary

The cannabis experience is preparation-dependent in a way few other plants are. Smoked or vaporised flower delivers rapid-onset intoxication — heightened senses, looser associations, distorted time, and a cerebral quality that peaks within minutes and fades over one to three hours. Edibles produce something meaningfully different: slower onset, deeper sedation, more body-prominent effects, and a longer, less predictable curve. Chemotype matters too — THC-dominant preparations produce the classical intoxication, while CBD-dominant preparations produce none at all.

Among widely consumed psychoactives, cannabis is the only plant-derived substance that works primarily through the endocannabinoid system, distinguishing it from alcohol, opioids, and serotonergic psychedelics. Synthetic cannabinoids share the same target but act as full agonists with a dramatically narrower safety margin.[5]

Archaeological evidence places cannabis domestication in East Asia during the early Neolithic,[3] with medicinal use documented across Asia well before the common era.[4] Modern cannabinoid science accelerated after Raphael Mechoulam's structural determination of THC in the mid-1960s. Cannabis remains Schedule I under US federal law despite recreational legality in 25 states; Canada legalised adult use nationally in 2018, and Germany followed with partial legalisation in 2024.

Subjective effects include cognitive euphoria, altered time perception, sensory enhancement, appetite stimulation, and anxiolysis.[5] The experience varies substantially by preparation — smoked flower produces rapid, cerebrally-prominent intoxication, while edibles deliver a slower, more sedating arc shaped by first-pass metabolism to active 11-OH-THC.[6] Anxiety, paranoia, and thought disorganisation emerge at higher doses or in susceptible individuals.[5]

Cannabis use disorder develops in approximately 9% of users, though acute toxicity is exceptionally low — no human fatality from cannabis alone is documented.[7] The primary chronic risks are psychological dependence with a recognised withdrawal,[8] cannabinoid hyperemesis syndrome in heavy users,[9] and dose-dependent psychosis risk amplified by high-potency preparations.[10] Clinical evidence is extensive for smoked flower and oral preparations but remains absent for high-potency concentrates.

History[edit]

Traditional and historical use

Cannabis is among the oldest cultivated plants. Genomic evidence traces all modern hemp and drug cultivars to an ancestral gene pool domesticated in East Asia during the early Neolithic.[3] Cannabis fibre impressed into pottery dates to approximately 10,000 BCE in present-day Taiwan, with cultivation for fibre, food, oil, and psychoactive resin spreading across Central and South Asia over subsequent millennia.[11]

In India, three principal preparations — bhang (oral leaf paste or drink), ganja (dried female inflorescences), and charas (hand-rubbed resin) — have been documented in ritual, recreational, and medical contexts since the Vedic period.[4] Cannabis was listed in the Shennong Bencao Jing (compiled circa 100 CE) for over 100 conditions. By the 13th century, hashish was widely described by Arab scholars across the Middle East and Central Asia. These are historical and cultural facts; traditional-use accounts are not evidence of therapeutic safety or efficacy.

Western discovery and research

William B. O'Shaughnessy introduced cannabis medicine to European practice in 1839 after observing its use in India.[4] Cannabis tinctures entered Western pharmacopeias in the mid-19th century but declined due to inconsistent potency and the rise of injectable pharmaceuticals.[4]

Modern cannabinoid science began when Raphael Mechoulam isolated and determined the structure of Δ9-THC in the mid-1960s.[4] Subsequent milestones include identification of the CB1 (1988), its localisation in brain tissue by quantitative autoradiography,[12] discovery of anandamide as the first endogenous cannabinoid (1992), and identification of 2-arachidonoylglycerol as a second endogenous CB1/CB2 ligand (1995).[13]

Modern era

The US Marihuana Tax Act of 1937 effectively prohibited cannabis nationally. It was placed in Schedule I of the UN 1961 Single Convention on Narcotic Drugs[14] and Schedule I of the US Controlled Substances Act in 1970.[15] California became the first US state to legalise medical cannabis in 1996; Colorado and Washington legalised recreational use in 2012.[16]

In December 2020, the UN Commission on Narcotic Drugs voted 27–25–1 to remove cannabis from Schedule IV of the 1961 Convention while retaining its Schedule I listing.[14] Canada enacted the Cannabis Act in October 2018, becoming the first major industrialised country to legalise adult recreational use nationally.[17] Germany followed with partial legalisation in April 2024.[18] The US FDA approved Epidiolex (purified CBD) for Dravet and Lennox-Gastaut syndromes in 2018, and as of 2026, the US Department of Justice has initiated rescheduling of state-approved medical cannabis from Schedule I to Schedule III.[15]

Botanical Overview[edit]

The genus Cannabis is monotypic: the single accepted species is Cannabis sativa L., with C. indica Lam. and C. ruderalis Janisch. treated as synonyms.[19] Whether indica and ruderalis merit subspecies or varietal rank remains debated; McPartland (2018) proposes two subspecies — subsp. sativa (fibre/hemp, CBD-dominant) and subsp. indica (drug-type, THC-dominant).[20] Vernacular strain names used in retail cannabis — "sativa" and "indica" — do not correspond reliably to botanical taxonomy due to generations of hybridisation.[20]

Cannabis is native to Central Asia, with genomic analysis confirming East Asia as the centre of domestication.[3] It is now cultivated or naturalised across six continents in temperate and subtropical climates, with major production regions including Afghanistan, Morocco, China, the Netherlands, Canada, and multiple US states.[19]

Cannabis sativa is an annual herb, typically dioecious — male and female flowers borne on separate plants — though monoecious variants occur.[11] Cannabinoid production concentrates in the glandular trichomes of female inflorescences; seeds, roots, and fan leaves contain negligible psychoactive material.[1] Hemp (THC < 0.3% dry weight) is visually indistinguishable from high-THC drug-type cannabis without chemical analysis. Three chemotypes are formally recognised: Type I (THC-dominant, 15–30%+ THC in commercial flower), Type II (balanced THC:CBD, uncommon in commercial markets), and Type III (CBD-dominant, legally classified as hemp in most jurisdictions).[20]

Alkaloid Profile[edit]

Cannabis produces over 100 phytocannabinoids alongside hundreds of terpenes and flavonoids.[21][1] These compounds concentrate in the glandular trichomes of the female flower and exist primarily as carboxylic acid precursors (THCA, CBDA) in the raw plant; smoking, vaporising, or cooking triggers thermal decarboxylation to their pharmacologically active neutral forms.[22]

THC (Δ9-tetrahydrocannabinol) is the primary psychoactive constituent, acting as a partial agonist at both CB1 and CB2 cannabinoid receptors.[21][23] THC content ranges from < 1% in hemp to > 30% in high-potency drug cultivars; modern concentrates reach 50–90%+ THC.[24] Cannabidiol (cannabidiol), the second most abundant cannabinoid in drug-type varieties, is non-intoxicating — it modulates CB1 activity as a negative allosteric modulator, partially activates 5-HT₁A serotonin receptors, and activates TRPV1 channels.[21][25] At CBD:THC ratios up to 3:1, CBD does not significantly attenuate the acute adverse effects of 10 mg THC in controlled trials of infrequent users.[5]

Minor cannabinoids include CBG (cannabigerol), the biosynthetic precursor to THC, CBD, and CBC, which activates TRPV1 and TRPV2 channels;[26] CBC (cannabichromene), a non-intoxicating TRPA1 agonist with preclinical anti-inflammatory properties;[26] CBN (cannabinol), a THC degradation product formed by oxidation in aged cannabis with mild sedative effects;[26] and THCV (tetrahydrocannabivarin), which antagonises CB1 at low doses and may suppress appetite in preclinical models.[23]

Cannabis terpenes — including β-myrcene, D-limonene, β-caryophyllene, linalool, and pinene — contribute to the plant's pharmacological character. Terpenes act as partial agonists at CB1 and CB2 receptors,[27] and D-limonene selectively mitigated THC-induced anxiety in a controlled crossover study of intermittent cannabis users.[27]

Potency varies significantly across cultivars, harvest batches, and growing conditions. Commercial product labels may deviate by ±15% or more from actual THC content,[28] and analytical discrepancies between different laboratory methods compound this uncertainty.[29]

Neuroscience[edit]

Where it acts

THC hijacks the endocannabinoid system (ECS), a retrograde signalling network in which lipid messengers — anandamide and 2-arachidonoylglycerol — travel backward across synapses to briefly inhibit neurotransmitter release.[13] THC replaces this phasic, on-demand signalling with sustained CB₁ activation, producing prolonged modulation of glutamate, GABA, dopamine, and acetylcholine release.[2] CB₁ receptors are densely expressed in the hippocampus (memory), prefrontal cortex (executive function), basal ganglia (movement and reward), cerebellum (coordination), and amygdala (emotional processing).[12] This distribution explains the characteristic signature: impaired short-term memory, altered executive processing, euphoria, motor clumsiness, and bidirectional anxiety modulation.

What it changes

CBD operates through a distinct target set — negative allosteric modulation of CB₁, partial 5-HT₁A agonism (an anxiolytic mechanism), and TRPV1 activation — without producing intoxication.[25][21] With repeated THC exposure, CB₁ receptors downregulate and desensitise, driving tolerance.[30] Oral preparations add a pharmacokinetic layer: first-pass hepatic metabolism converts THC to 11-OH-THC, a metabolite that crosses the blood-brain barrier more efficiently and likely contributes to the intensified, prolonged experience of edibles.[6]

Subjective Effects[edit]

Summary

The cannabis experience is unusually preparation-dependent. Smoked or vaporised flower delivers a rapid, cerebrally-prominent intoxication — heightened sensory salience, associative loosening, and time dilation peaking within minutes and resolving over one to three hours. Edibles produce a qualitatively different arc: slower onset (often 60+ minutes), deeper sedation, more body-prominent effects, and a longer, less controllable intensity curve shaped by 11-OH-THC formation. Chemotype matters nearly as much as route — THC-dominant cultivars produce the classical intoxication, while CBD-dominant preparations produce no recognised intoxication. Set, setting, and individual tolerance all modulate the experience substantially.

Among widely consumed psychoactives, cannabis occupies a distinctive niche as the only plant-derived CB₁ partial agonist in common recreational use — distinguishing it from synthetic cannabinoids (full agonists with dramatically narrower safety margins) and from alcohol, which produces less perceptual distortion but greater motor impairment at typical doses, with a far narrower margin of acute toxicity.[7]

Effect Grid

Dose Level:
Description

Clear cognitive euphoria — the recognisable cannabis 'high' — is established at the common tier. Music enhancement and taste enhancement are pronounced. Time alteration is reliable (subjective time dilation). Creativity enhancement, immersion enhancement, and thought connectivity emerge. Internal hallucinations may appear as mild closed-eye imagery. Conceptual thinking and novelty enhancement colour the experience.

Dry mouth and appetite enhancement ('the munchies') are prominent. Tachycardia (abnormal heartbeat) is consistent. Sedation appears, particularly with indica-leaning chemotypes. Motor control impairment is noticeable. Spontaneous body sensations and muscle relaxation contribute to a distinct body high.

Memory suppression (short-term) is clearly present. Focus suppression is typical. Anxiety is possible in susceptible individuals, particularly naive users or those in uncomfortable settings. This tier represents the standard recreational experience for most users.

Modeled from the effect's dose-dependence curve — not per-substance measurements.

Perception(37)likelihood · intensity
Music enhancement
likely
Dreaming suppression
possible
Auditory enhancement
possible
Touch enhancement
possible
Taste enhancement
possible
Vestibular distortion
possible
Visual acuity suppression
possible
Brightness alteration
possible
Double vision!
rare

Taste enhancement · Vestibular distortion · Visual acuity suppression · Brightness alteration · Auditory distortion · Color alteration · Color enhancement · Spatial disorientation · Peripheral misidentification · Depth perception distortion · Perspective distortion · Proprioceptive distortion · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Tracers · Geometry · After-images · Auditory misinterpretation · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual breathing · Visual drifting · Synesthesia · Visual processing suppression · Flashbacks · Internal hallucinations · Auditory hallucinations · Object activation · External hallucinations · Persisting hallucinations

Auditory distortion · Color alteration · Color enhancement · Spatial disorientation · Peripheral misidentification · Depth perception distortion · Perspective distortion · Proprioceptive distortion · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Tracers · Geometry · After-images · Auditory misinterpretation · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual breathing · Visual drifting · Synesthesia · Visual processing suppression · Flashbacks · Internal hallucinations · Auditory hallucinations · Object activation · External hallucinations · Persisting hallucinations

Body(44)likelihood · intensity
Dry mouth
likely
Body high
likely
Heart rate perception changes
likely
Motor control impairment!
possible
Muscle relaxation
possible
Sedation
possible
Bodily heaviness
possible
Abnormal heartbeat!
possible
Temperature dysregulation!
rare

Muscle relaxation · Sedation · Bodily heaviness · Appetite enhancement · Body scan awareness · Pain suppression · Nausea suppression · Spontaneous body sensations · Laughter fits · Physical fatigue · Dizziness · Bodily lightness · Tactile euphoria · Dehydration sensation · Breathing alteration · Pupil dilation · Sexual arousal enhancement · Stimulation · Bodily pressures · Respiratory stimulation · Excessive sweating · Insomnia · Nausea · Sexual arousal suppression · Body schema distortion · Headache · Nystagmus (eye wobbles) · Restlessness · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Watery eyes · Appetite suppression · Involuntary body movements · Trembling · Vomiting · Seizure threshold reduction · Bodily dissociation

Appetite enhancement · Body scan awareness · Pain suppression · Nausea suppression · Spontaneous body sensations · Laughter fits · Physical fatigue · Dizziness · Bodily lightness · Tactile euphoria · Dehydration sensation · Breathing alteration · Pupil dilation · Sexual arousal enhancement · Stimulation · Bodily pressures · Respiratory stimulation · Excessive sweating · Insomnia · Nausea · Sexual arousal suppression · Body schema distortion · Headache · Nystagmus (eye wobbles) · Restlessness · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Watery eyes · Appetite suppression · Involuntary body movements · Trembling · Vomiting · Seizure threshold reduction · Bodily dissociation

Thinking(42)likelihood · intensity
Cognitive euphoria
likely
Memory suppression
likely
Focus suppression
possible
Immersion enhancement
possible
Thought connectivity
possible
Aesthetic enhancement
possible
Decision impairment!
possible
Suggestibility enhancement!
possible
Compulsive redosing urge!
possible

Immersion enhancement · Thought connectivity · Aesthetic enhancement · Cognitive impairment · Novelty enhancement · Conceptual thinking · Openness enhancement · Humor enhancement · Analysis suppression · Creativity enhancement · Motivation suppression · Thought deceleration · Cognitive fatigue · Increased nature relatedness · Information processing suppression · Introspection enhancement · Memory fragmentation · Thought disorganization · Pattern recognition enhancement · Cognitive flexibility · Compulsive redosing urge · Confusion · Language suppression · Multiple thought streams · Thought loops · Analysis enhancement · Cognitive dysphoria · Memory replays · Pattern recognition suppression · Language enhancement · Delusions of sobriety · Synchronicity · Focus enhancement · Motivation enhancement · Amnesia · Delusions · Delirium

Cognitive impairment · Novelty enhancement · Conceptual thinking · Openness enhancement · Humor enhancement · Analysis suppression · Creativity enhancement · Motivation suppression · Thought deceleration · Cognitive fatigue · Increased nature relatedness · Information processing suppression · Introspection enhancement · Memory fragmentation · Thought disorganization · Pattern recognition enhancement · Cognitive flexibility · Confusion · Language suppression · Multiple thought streams · Thought loops · Analysis enhancement · Cognitive dysphoria · Memory replays · Pattern recognition suppression · Language enhancement · Delusions of sobriety · Synchronicity · Focus enhancement · Motivation enhancement · Amnesia · Delusions · Delirium

Feeling(9)likelihood · intensity
Euphoria
likely
Emotional enhancement
possible
Anxiety
possible
Paranoia!
possible
Anxiety suppression
possible
Emotional lability
possible
Empathy enhancement
possible
Simultaneous emotions
possible
Dysphoria
rare

Emotional lability · Empathy enhancement · Simultaneous emotions · Dysphoria

Self(15)likelihood · intensity
Craving
possible
Disinhibition
possible
Emotional susceptibility
possible
Sociability enhancement
possible
Social connection
possible
Trust enhancement
possible
Communication enhancement
possible
Flow state
possible
Self-control suppression!
rare

Social connection · Trust enhancement · Communication enhancement · Flow state · Depersonalization · Derealization · Communication suppression · Cognitive disconnection · Boundary dissolution · Ego dissolution

Depersonalization · Derealization · Communication suppression · Cognitive disconnection · Boundary dissolution · Ego dissolution

Time(5)likelihood · intensity
Time alteration
likely
Present-moment absorption
possible
Temporal disorientation
possible
Deja vu
rare
Jamais vu
rare
Transpersonal(3)likelihood · intensity
Unity and interconnectedness
rare
Noetic insight
v.rare
Existential realization
v.rare
Awareness(3)likelihood · intensity
Personal insight
possible
Mindfulness enhancement
possible
Reality testing impairment!
v.rare
report missing effect
Likelihood: how common this effect is at the selected dose level.This effect has safety implications — review before use.

Timeline

Preparations[edit]

Cannabis preparations differ enormously in onset, intensity, duration, and risk profile. Dose and preparation are inseparable — a 10 mg THC edible behaves nothing like 10 mg THC from smoked flower.

  • Flower (smoked) — dried female inflorescences combusted in a joint, pipe, or water pipe. Commercial flower typically contains 15–30% THC in drug-type cultivars. Bioavailability approximately 10–35%.[29] Onset within seconds to 2 minutes; peak at 5–15 minutes; duration 1–4 hours.[30] Rapid-onset and cerebrally prominent. Combustion produces respiratory irritants and the highest acute cardiovascular stress of any preparation.[31]
  • Flower (vaporised) — flower heated to 170–210°C without combustion. Bioavailability comparable to smoking; highest peak plasma concentration of any preparation.[32] Onset, peak, and duration mirror smoked flower. Avoids combustion byproducts; significantly lower respiratory irritation.[31]
  • Concentrates (dabs, wax, shatter) — high-potency extracts containing 50–90%+ THC.[21] A single inhalation delivers far more THC than flower. Onset in seconds; duration 1–4 hours. Emergent psychosis has been reported following concentrate use in individuals with no prior psychiatric history.[33] Improperly purged butane extracts may contain residual solvents. safety citation needed No controlled clinical trial data characterise dose-response for concentrates in human subjects.
  • Edible (oral) — THC in food, capsules, or oils. Standard regulated serving in US and Canadian markets is 10 mg THC. Oral bioavailability is low (4–12%) due to first-pass hepatic metabolism, which converts THC to 11-OH-THC — a compound that crosses the blood-brain barrier more efficiently.[28][29] Onset 30 minutes to 2+ hours; peak at 2–4 hours; duration 4–8 hours, occasionally longer in naive users.[29] Delayed onset is the primary cause of accidental overconsumption. Effects are more sedating and body-prominent than inhaled preparations.[31]
  • Oromucosal spray (Sativex/nabiximols) — standardised pharmaceutical spray delivering 2.7 mg THC + 2.5 mg CBD per actuation. Pharmacokinetics intermediate between inhalation and oral.[32] Approved in Canada and multiple European countries for central neuropathic pain in multiple sclerosis.

Onset and intensity differ substantially between preparations — edibles take 30–90 minutes to reach full effect while smoked preparations act within minutes.

Safety[edit]

Harm
Acute toxicity
Low
Chronic toxicity
Moderate
Withdrawal
Moderate
Tolerance buildup
moderate
Tolerance reset
17.5 days
Dependence
Physical
Moderate
Psychological
Moderate
Compulsive redosing
Low
Dose escalation
Moderate
Cross-tol.
Synthetic cannabinoids · Other plant-derived CB1 agonists
Risk Shape
TOXPHYPSYWDRREDTOL

Toxicity

No human fatality from cannabis alone has been documented. Comparative risk analysis places cannabis at a margin of exposure exceeding 10,000 — far above the threshold of acute lethal concern.[5] Acute adverse effects in controlled trials include dizziness, dry mouth, nausea, headache, confusion, loss of balance, and tachycardia.[34] At high doses or with high-potency preparations, disorientation and acute psychotic episodes may occur.[33][8]

Tachycardia is the most consistent cardiovascular effect across all routes.[31] Ventricular arrhythmias and heart attack have been reported, particularly with concurrent tobacco use.[31] Cardiac risk increases with stimulant co-administration.[29]

Chronic cannabis smoking is strongly associated with chronic bronchitis.[35][36] No convincing causal link to COPD or lung cancer has been established, though concurrent tobacco use amplifies respiratory risks.[37] Immunocompromised users face risk of invasive pulmonary aspergillosis.[35]

Cannabinoid hyperemesis syndrome (CHS) — recurrent cyclic vomiting in heavy chronic users — is increasingly recognised in emergency settings.[38] Episodes worsen with continued use; full remission requires sustained abstinence.[7] Acute management includes hot showers, haloperidol (up to 5 mg intramuscular), and topical capsaicin cream (0.075–0.1%).[7]

Commercial cannabis carries contamination risks beyond its intrinsic pharmacology. Pesticide residues have been detected in commercial samples.[39] Cannabis can accumulate heavy metals through soil uptake.[40] Aspergillus species pose particular concern for immunocompromised users.[35] THC concentrations on labels may deviate ±15% or more from actual content.[25][26][41] Butane hash oil may contain residual solvents if improperly purged. Synthetic cannabinoid adulteration is a risk in illicit markets.

Psychological Risks

Epidemiological evidence supports a dose-response relationship between cannabis use and psychosis risk; high-potency preparations confer the greatest risk.[8][42] Genetic vulnerability interacts with cannabis as a component cause in psychosis.[42] Psychosis associated with cannabis withdrawal has also been documented.[43]

Acute anxiety and paranoia are common dose-dependent adverse effects, especially in infrequent users and with high-THC preparations.[4] Intoxication impairs short-term memory, attention, and executive function.[34] Adolescent cannabis exposure is associated with enduring cognitive deficits and increased psychiatric risk.[8]

Tolerance & Dependence

Tolerance develops through CB1 downregulation with prolonged use.[2][27] Cannabis dependence is the most common drug use disorder globally after opioid dependence — an estimated 22.1 million cases in 2016.[44] Approximately 50% of regular users experience withdrawal symptoms after abrupt cessation.[6][45]

Symptoms — irritability, anxiety, insomnia, reduced appetite, restlessness, and low mood[43] — begin 1–3 days after stopping, peak at 2–6 days, and resolve within 2–3 weeks.[6] No approved pharmacotherapy for cannabis use disorder exists as of 2026.

Drug Interactions

Warfarin: THC and CBD slow the enzyme that breaks down warfarin, potentially raising warfarin levels and bleeding risk.[46]

Benzodiazepines and other CYP3A4-metabolised drugs: CBD slows breakdown of these drugs, increasing their plasma levels.[46][29]

Clobazam: CBD specifically slows clobazam metabolism — a clinically documented interaction relevant to epilepsy patients.[46]

Opioids: Cannabis augments opioid pain suppression through additive effects but also adds CNS depression.[47]

GABAergic anaesthetics: Regular cannabis users consistently require higher anaesthetic doses; the mechanism is unclear.[48]

Sympathomimetics: Additive elevated heart rate and blood pressure, increasing cardiac risk.[29]

Tobacco: Co-use synergistically amplifies respiratory risks.[37]

Alcohol: Combined use substantially increases driving impairment beyond either substance alone.citation needed Additive sedation expected.

Contraindications

Pregnancy is an absolute contraindication. Prenatal cannabis exposure is associated with lower birth weight, increased preterm birth risk, and NICU admission.[49][50][51] THC crosses the placenta and interacts with fetal cannabinoid receptors,[51] and long-term follow-up documents effects on memory and behaviour in offspring.[52] Professional bodies universally advise against cannabis during pregnancy.[51]

Adolescence is a relative contraindication due to the developing brain's heightened vulnerability.[8]

Personal or family history of psychotic disorders is a strong relative contraindication.[8][42]

Significant cardiovascular disease is contraindicated due to tachycardia and arrhythmia risk.[29][31]

Hepatic impairment warrants caution: THC and CBD are extensively metabolised by the liver.[29]

Detection

The main urinary marker is 11-nor-9-carboxy-THC (THCCOOH), an inactive metabolite.[53][54] The standard US federal workplace cutoff is 50 ng/mL.[54] Detection windows vary with use frequency: infrequent use may remain detectable 3–7 days; regular use 7–21 days; chronic daily use 30+ days, sometimes months, due to lipophilic tissue storage.[53] A positive urine result confirms prior exposure — not current impairment.[54] Synthetic cannabinoids are not detected by standard cannabinoid immunoassays.

Harm Reduction[edit]

Forms & Identification

Reagent ResultsNot recorded+ add reagent results
AppearanceNot recorded+ add appearance
Red FlagsNot recorded+ add red flags

Cannabis preparations range from dried flower to highly processed concentrates, and potency varies enormously across products. Request a Certificate of Analysis (COA) from lab-tested products — this shows cannabinoid potency, pesticide screening, heavy metal testing, and residual solvent analysis. For unregulated-market flower, there is no reliable way to estimate THC content visually. Concentrates amplify potency uncertainty: a small dosing error translates to a far larger THC exposure than with flower.

Full identification analysis →

Guidelines

  • Start low, go slow — with edibles, begin with 2.5–5 mg THC and wait at least 2 hours before considering a second dose; with concentrates, use the smallest available amount for a first experience
  • Know the product — verify THC and CBD content from lab testing when possible; do not rely on strain names as potency indicators
  • Hydrate — dry mouth is near-universal; keep water accessible
  • Avoid combining cannabis with alcohol, opioids, or sedatives — these combinations amplify impairment and risk
  • Do not smoke with respiratory conditions — vaporisation or edibles are lower-risk alternatives for the lungs
  • Use in a safe location — do not drive, operate heavy machinery, or swim while intoxicated
  • Tolerance breaks — regular users who wish to reduce tolerance can abstain for 2–4 weeks; most subjective tolerance resets within this window, though precise CB1 recovery timelines are not definitively established

Set & Setting

Cannabis effects are strongly context-dependent. A familiar, comfortable environment with trusted companions reduces the likelihood of anxiety or paranoia — especially for infrequent users or those trying a new preparation. High-potency products (concentrates, flower above 20% THC) increase the risk of acute anxiety and disorientation. Edible onset is unpredictable and may take 90+ minutes — using edibles where sobriety is quickly needed is inadvisable. Driving under the influence of cannabis is unsafe; impairment persists beyond the subjective peak.

Aftercare & integration. After a cannabis experience — particularly an intense or edible-mediated one — residual grogginess, mental fog, or low mood may persist the next day. These are not dangerous:

  • Hydrate and eat — appetite and hydration often suffer during the acute phase
  • Sleep — fatigue is common; allow extra rest if possible
  • Assess the experience — if the session involved unexpected anxiety, paranoia, or loss of control, consider whether the dose, preparation, or setting contributed, and adjust future use accordingly
  • Edible-specific: effects may linger for 8+ hours; plan accordingly and avoid obligations requiring full cognitive function during this window

Recovery & Support

Cannabis use disorder affects approximately 9% of users. If cannabis use has become difficult to control, causes distress, or interferes with daily functioning, evidence-based support is available:

  • Cognitive behavioural therapy (CBT) and motivational enhancement therapy (MET) are first-line treatments for cannabis use disorder
  • SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7 in the US)
  • Cannabis withdrawal — irritability, insomnia, reduced appetite, and anxiety typically peak at days 2–6 and resolve within 2–3 weeks; symptoms are uncomfortable but not medically dangerous
  • Gradual reduction — tapering over 1–2 weeks before full cessation can reduce withdrawal intensity
  • No approved pharmacotherapy for cannabis use disorder exists as of 2026; psychosocial interventions remain the primary treatment

Recovery resources, crisis lines, and support pathways → View all

Emergency Response

Cannabis emergencies are rarely life-threatening, but acute distress can be severe. Recognise these warning signs:

  • Severe paranoia or panic that does not respond to reassurance
  • Chest pain, rapid or irregular heartbeat, or difficulty breathing
  • Signs of psychotic break: loss of contact with reality, hallucinations, incoherent speech
  • Repeated vomiting lasting hours (possible cannabinoid hyperemesis syndrome)
  • Unresponsiveness or seizure

Immediate steps:

  • 1. Move the person to a quiet, safe space. Speak calmly.
  • 2. If panic or paranoia: remind them the effects are temporary and will pass. Cold water on the face or hands can help ground them.
  • 3. If chest pain, breathing difficulty, seizure, or unresponsiveness: call emergency services immediately.
  • 4. If repeated vomiting (possible CHS): a hot shower may provide temporary relief. Seek medical attention if vomiting persists beyond several hours.
  • 5. Do not leave an intoxicated person alone if they are confused or distressed.

What to tell the dispatcher: the substance (cannabis — specify preparation and approximate amount if known), time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect individuals who call for help during a drug-related emergency.

There is no reversal agent for cannabis intoxication. Management is supportive.

Preparations[edit]

Cannabis effects depend strongly on preparation type, THC percentage, CBD:THC ratio, individual tolerance, and set and setting. The Dose · by preparation card on this page provides structured dose tiers; the following sections describe the pharmacological character that dose numbers alone do not convey.

Flower (smoked)

Dried female inflorescences combusted in a joint, pipe, or water pipe. Commercial flower typically contains 15–30% THC in drug-type cultivars. Bioavailability is approximately 10–35%, highly variable with inhalation technique.[31] Onset occurs within seconds to two minutes, with peak effects at 5–15 minutes and total duration of 1–4 hours.[32] The experience is rapid-onset and cerebrally prominent. Combustion produces tar, carbon monoxide, and respiratory irritants, and smoked flower carries the highest acute cardiovascular stress (tachycardia) among all preparations.[33]

Flower (vaporised)

Dried flower heated to 170–210°C without combustion, releasing cannabinoids and terpenes as vapour. Bioavailability is comparable to smoking, with the highest peak plasma concentration of any preparation.[34] Onset, peak, and duration mirror smoked flower. Vaporisation avoids combustion byproducts and is associated with significantly reduced respiratory irritation.[33]

Concentrated extracts

High-potency preparations (wax, shatter, oil, dabs) containing 50–90%+ THC, produced through solvent extraction or mechanical separation.[24] Dabbing involves flash-vaporisation on a heated surface, delivering dramatically higher THC per inhalation than flower. Onset is seconds; duration 1–4 hours. Case reports document emergent psychosis following dab use in individuals without prior psychiatric history.[35] Residual solvents may be present in improperly purged butane hash oil preparations. safety citation needed No controlled clinical trial data characterise dose-response for cannabis concentrates in human subjects.

Edible (oral)

THC incorporated into food products, capsules, or oils. The standard regulated serving in US state and Canadian markets is 10 mg THC per unit. Oral bioavailability is low (4–12%) due to first-pass hepatic metabolism, which produces the active metabolite 11-OH-THC — a compound that crosses the blood-brain barrier more efficiently than THC and likely contributes to the heightened intensity of oral preparations.[6][31] Onset is 30 minutes to 2+ hours; peak at 2–4 hours; duration 4–8 hours, occasionally longer in naive users.[31] Delayed onset frequently leads to unintentional overconsumption. Effects tend to be more sedating and body-prominent than inhaled preparations, with minimal respiratory and cardiovascular effects.[33]

Oromucosal spray (Sativex/nabiximols)

Standardised pharmaceutical spray delivering 2.7 mg THC + 2.5 mg CBD per actuation. Partially bypasses first-pass hepatic metabolism; pharmacokinetics intermediate between inhalation and oral.[34] Approved in Canada and multiple European countries for central neuropathic pain in multiple sclerosis.

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

Safety[edit]

Harm
Acute toxicity
Low
Chronic toxicity
Moderate
Withdrawal
Moderate
Tolerance buildup
moderate
Tolerance reset
17.5 days
Dependence
Physical
Moderate
Psychological
Moderate
Compulsive redosing
Low
Dose escalation
Moderate
Cross-tol.
Synthetic cannabinoids · Other plant-derived CB1 agonists
Risk Shape
TOXPHYPSYWDRREDTOL

Toxicity

No human fatality from cannabis alone has been documented in the published literature. Comparative risk assessment using the margin of exposure approach places cannabis at an MOE exceeding 10,000.[7] Acute adverse effects observed in controlled trials include dizziness, dry mouth, headache, dry eyes, nausea, somnolence, confusion, loss of balance, and tachycardia.[36] At high doses or with high-potency preparations, disorientation and acute psychotic episodes may occur in susceptible individuals.[35][10]

Tachycardia is the most consistent cardiovascular effect across all routes of administration.[33] Ventricular arrhythmias and myocardial infarction have been reported, particularly with concurrent tobacco use.[33] Cardiac toxicity risk is amplified by co-administration with sympathomimetic agents.[31]

Chronic cannabis smoking is strongly associated with chronic bronchitis — increased mucus production, cough, and airway inflammation.[37][38] No convincing causal link to COPD has been established, and the association with lung cancer remains inconclusive; concurrent tobacco use amplifies respiratory risks synergistically.[39] Cannabis smoke has been associated with invasive pulmonary aspergillosis in immunocompromised individuals.[37] Vaporisation avoids combustion byproducts; edibles carry minimal respiratory risk.[33]

Cannabinoid hyperemesis syndrome (CHS) is a condition of recurrent cyclic vomiting associated with chronic heavy cannabis use, increasingly recognised in emergency departments.[40] Full remission requires sustained cannabis abstinence; relapses cause progressively stronger and longer episodes (sensitisation).[9] Acute management includes hot showers (a diagnostic criterion), haloperidol (up to 5 mg intramuscular), and topical capsaicin cream (0.075–0.1%).[9]

Cannabis preparations sold in both regulated and unregulated markets carry contamination risks distinct from intrinsic pharmacological toxicity. Pesticide residues have been detected in commercial cannabis samples; US state regulations vary widely in allowable limits and enforcement.[41] Cannabis can accumulate heavy metals (lead, cadmium, nickel) through soil uptake.[42] Aspergillus species pose particular concern for immunocompromised consumers.[37] THC concentrations on product labels may deviate ±15% or more from actual content.[28][29][43] Butane hash oil may contain residual solvents if improperly purged. Synthetic cannabinoid adulteration is a risk in illicit markets. ISO/IEC-accredited third-party testing is required in most US state-regulated markets, but standards and enforcement vary by jurisdiction.[41] No federal testing standard exists in the United States.

Psychological Risks

Epidemiological evidence consistently supports a dose-response relationship between cannabis use and psychosis risk; high-potency varieties confer the greatest risk.[10][44] Cannabis functions as a component cause in multi-causal psychosis models, where genetic vulnerability interacts with the precipitating substance.[44] Psychosis associated with cannabis withdrawal has also been documented in a systematic review.[45] Two case reports document emergent psychosis following use of high-potency wax concentrates in individuals without prior psychiatric history.[35]

Acute anxiety and paranoia are common dose-dependent adverse effects, particularly in infrequent users and with high-THC preparations.[5] Acute intoxication impairs short-term memory, attention, and executive function.[36] Chronic heavy use is associated with reduced attentional and executive function, decreased cognitive flexibility, and increased perseveration.citation needed Adolescent cannabis exposure is associated with enduring cognitive deficits, mesocorticolimbic dysregulation, and increased psychiatric risk.[10]

Tolerance & Dependence

Tolerance develops through CB1 downregulation and desensitisation with prolonged use.[2][30] Cross-tolerance within cannabinoids is established. Specific recovery timelines for CB1 receptor function vary across individuals and have not been definitively established in a single published human study. safety citation needed The tolerance half-life and full-reset values in the existing database (1.5 weeks and 2.5 weeks, respectively) could not be verified against a specific published primary source.

Cannabis dependence is the most common drug use disorder globally after opioid dependence, with an estimated 22.1 million cases in 2016.[46] Approximately 9% of cannabis users develop cannabis use disorder; risk increases with earlier initiation and daily use.citation needed Cannabis withdrawal syndrome (CWS) is a DSM-5-recognised condition occurring in approximately 50% of regular and dependent users after abrupt cessation or significant dose reduction.[8][47] Symptoms include irritability, anxiety, insomnia, reduced appetite, restlessness, and depressed mood.[45] Onset is typically 1–3 days after cessation, peak severity at 2–6 days, and resolution within 2–3 weeks.[8]

No approved pharmacotherapy for cannabis use disorder exists as of 2026. Psychosocial interventions remain first-line treatment.

Drug Interactions

Cannabis interacts with other substances through both pharmacokinetic (CYP enzyme inhibition) and pharmacodynamic (additive CNS effects) mechanisms.

Warfarin (CYP2C9): THC and CBD inhibit CYP2C9 competitively in a dose-dependent manner, potentially increasing warfarin levels and bleeding risk.[48]

Midazolam and other CYP3A4 substrates: CBD inhibits CYP3A4 noncompetitively, which may increase plasma levels of benzodiazepines and other CYP3A4-metabolised drugs.[48][31]

Clobazam: CBD specifically inhibits clobazam metabolism, a clinically documented interaction relevant to epilepsy patients.[48]

Opioids (morphine, oxycodone): Vaporised cannabis augments opioid analgesic effects through pharmacodynamic synergism, reducing pain by an average of 27% in a controlled study without significantly altering plasma opioid levels.[49] Additive CNS depression is the principal risk.

Benzodiazepines (diazepam): Additive CNS depression and enhanced sedation expected through pharmacodynamic mechanism. safety citation needed No specific clinical case report for a cannabis–diazepam interaction was identified; caution is mechanism-based.

GABAergic anaesthetics (propofol, midazolam, isoflurane, sevoflurane): Cannabis users consistently require increased anaesthetic doses; the molecular mechanism remains unclear.[50]

Sympathomimetics: Additive hypertension and tachycardia, increasing cardiac toxicity risk.[31]

Tobacco/nicotine: Co-use synergistically amplifies respiratory risks, including lung cancer risk.[39] The mechanism is pharmacodynamic (combined combustion exposure).

Alcohol: Combined use substantially increases driving impairment, with effects greater than either substance alone.citation needed Additive sedation is expected.

Contraindications

Pregnancy is an absolute contraindication. Prenatal cannabis exposure is significantly associated with lower birth weight, increased preterm birth risk, small-for-gestational-age neonates, and NICU admission.[51][52][53] THC crosses the placenta and interacts with fetal cannabinoid receptors.[53] Long-term follow-up documents effects on memory and externalising behaviours in offspring.[54] Professional bodies universally discourage cannabis use during pregnancy.[53]

Adolescence is a relative contraindication due to the developing brain's heightened vulnerability to enduring cognitive and psychiatric effects.[10]

Personal or family history of psychotic disorders is a strong relative contraindication due to the dose-dependent association between cannabis use and psychosis.[10][44]

Significant cardiovascular disease is contraindicated due to tachycardia and arrhythmia risk across all administration routes.[31][33]

Hepatic impairment warrants caution: THC and CBD are extensively hepatically metabolised, and impaired clearance is expected in liver disease.[31]

Detection

The primary urinary analyte is 11-nor-9-carboxy-THC (THCCOOH), an inactive metabolite.[55][56] Standard immunoassay cutoff for US federal workplace testing is 50 ng/mL.[56] Detection windows vary by use frequency: infrequent use (∼1 time per week) may remain positive for 3–7 days; regular use (several times per week) for 7–21 days; chronic daily use for 30+ days, and in some cases months, due to lipophilic tissue storage.[55]

Urine immunoassays show variable sensitivity (63–74% for moderate users) but excellent specificity.[57] Blood and plasma testing is preferred for assessing acute impairment.[57] A positive urine result confirms prior THC exposure; it does not document current impairment or recent use.[56] CBD-only preparations (hemp-derived, < 0.3% THC) should not trigger standard immunoassays, though labelling inaccuracies in commercial CBD products have led to unexpected positive results. Synthetic cannabinoids are not detected by standard cannabinoid immunoassays.

Harm Reduction[edit]

Forms & Identification

Reagent ResultsNot recorded+ add reagent results
AppearanceNot recorded+ add appearance
Red FlagsNot recorded+ add red flags

Cannabis preparations range from raw dried flower to highly processed concentrates, and potency varies enormously even within a single product category. Lab-tested products from ISO/IEC-accredited facilities provide the most reliable potency data — but even in regulated markets, label accuracy may deviate ±15% or more from actual THC content. For unregulated-market flower, there is no reliable way to estimate THC content visually. Concentrates amplify potency uncertainty: a small dosing error translates to a much larger THC exposure than with flower. When available, request or verify a Certificate of Analysis (COA) showing cannabinoid potency, pesticide screening, heavy metal testing, and residual solvent analysis.

Full identification analysis →

Guidelines

  • Start low, go slow — particularly with edibles (begin with 2.5–5 mg THC; wait at least 2 hours before considering a second dose) and concentrates (use the smallest available amount for a first experience)
  • Know your product — verify THC and CBD content from lab testing when possible; do not rely on strain names as potency indicators
  • Hydrate — dry mouth is near-universal; keep water accessible
  • Avoid combining cannabis with alcohol, opioids, or sedatives — these combinations amplify impairment and risk
  • Do not smoke if you have respiratory conditions — vaporisation or edibles are lower-risk alternatives for the lungs
  • Use in a safe location — do not drive, operate heavy machinery, or swim while intoxicated
  • Tolerance breaks — regular users who wish to reduce tolerance can abstain for 2–4 weeks; most subjective tolerance resets within this window, though precise CB1 recovery timelines are not definitively established

Set & Setting

Cannabis effects are strongly context-dependent. A familiar, comfortable environment with trusted companions reduces the likelihood of anxiety or paranoia — particularly for infrequent users or those trying a new preparation or higher-potency product. High-potency products (concentrates, high-THC flower above 20%) increase the risk of acute anxiety and disorientation and are not appropriate first experiences. Edible onset is unpredictable and may take 90+ minutes; consuming edibles in a setting where obligations require quick sobriety is inadvisable. Driving or operating machinery under the influence of cannabis is unsafe — impairment persists beyond the subjective peak.

Aftercare & integration. After a cannabis experience — particularly an intense or edible-mediated one — some users experience residual grogginess, mental fog, or low mood the following day. These effects are not dangerous but can be managed:

  • Hydrate and eat — appetite and hydration often suffer during the acute phase
  • Sleep — fatigue is common; allow extra rest if possible
  • Assess the experience — if the session involved unexpected anxiety, paranoia, or loss of control, consider whether the dose, preparation, or setting contributed, and adjust future use accordingly
  • Edible-specific: effects may linger for 8+ hours; plan accordingly and avoid obligations requiring full cognitive function during this window

Recovery & Support

Cannabis use disorder affects approximately 9% of users. If cannabis use has become difficult to control, causes distress, or interferes with daily functioning, evidence-based support is available:

  • Cognitive behavioural therapy (CBT) and motivational enhancement therapy (MET) are first-line psychosocial treatments for cannabis use disorder
  • SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7 in the US)
  • Cannabis withdrawal — irritability, insomnia, reduced appetite, and anxiety typically peak at days 2–6 and resolve within 2–3 weeks; symptoms are uncomfortable but not medically dangerous
  • Gradual reduction — tapering use over 1–2 weeks before full cessation can reduce withdrawal intensity
  • No approved pharmacotherapy for cannabis use disorder exists as of 2026; psychosocial interventions remain the primary treatment modality

Recovery resources, crisis lines, and support pathways → View all

Emergency Response

Cannabis emergencies are rarely life-threatening, but acute distress can be severe. Recognise these warning signs:

  • Severe paranoia or panic that does not respond to reassurance
  • Chest pain, rapid or irregular heartbeat, or difficulty breathing
  • Signs of psychotic break: loss of contact with reality, hallucinations, incoherent speech
  • Repeated vomiting lasting hours (possible cannabinoid hyperemesis syndrome)
  • Unresponsiveness or seizure

Immediate steps:

  • 1. Move the person to a quiet, safe space. Speak calmly.
  • 2. If panic or paranoia: remind them the effects are temporary and will pass. Cold water on the face or hands can help ground them.
  • 3. If chest pain, breathing difficulty, seizure, or unresponsiveness: call emergency services immediately.
  • 4. If repeated vomiting (possible CHS): a hot shower may provide temporary relief. Seek medical attention if vomiting persists beyond several hours.
  • 5. Do not leave an intoxicated person alone if they are confused or distressed.

What to tell the dispatcher: the substance (cannabis — specify preparation and approximate amount if known), time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect individuals who call for help during a drug-related emergency.

There is no reversal agent for cannabis intoxication. Management is supportive.

Frequently asked questions

What is Cannabis?

Cannabis is a cannabinoid-producing plant (Cannabis sativa L.) whose primary constituent, THC, is a CB1/CB2 partial agonist. It is the most widely consumed illicit psychoactive plant globally, with medicinal use documented since antiquity and modern research focused on pain, epilepsy, and psychiatric risk.

How long does Cannabis last?

Total duration by route of administration — Oral: 4 – 8 hours; Smoked: 1 – 4 hours; Sublingual: 3 – 6 hours; Vaporized: 1 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.

Where can I find dosage information for Cannabis?

Psychedex publishes a dosage table for Cannabis on this page covering these routes of administration: smoked, vaporized, oral, sublingual. Dose values are presented only in that table, always alongside their route of administration.

What are dangerous combinations with Cannabis?

The highest-severity documented interactions for Cannabis: GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous), Ketamine, DXM, PCP (Dangerous), Local anesthetics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.

Is Cannabis addictive?

Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Cannabis: tolerance builds moderate; full reset takes 17.5 days; cross-tolerance develops with Synthetic cannabinoids, Other plant-derived CB1 agonists. See the article's dependence and safety sections for recorded dependence data.

experience reports

No experience reports yet. Be the first to contribute.

First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.

references

  1. [1] 
    ^abcAndre CM, Hausman JF, Guerriero G (2016) Cannabis sativa: The Plant of the Thousand and One Molecules — Frontiers in Plant Science doi:10.3389/fpls.2016.00019
  2. [2] 
    ^abcHempel B, Xi ZX (2022) Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond — Advances in Pharmacology doi:10.1016/bs.apha.2021.10.006
  3. [3] 
    ^abcRen G, Zhang X, Li Y, Ridout K, Serrano-Serrano ML, Yang Y, Liu A, Ravikanth G, Nawaz MA, Mumtaz AS, Salamin N, Fumagalli L (2021) Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa — Science Advances doi:10.1126/sciadv.abg2286
  4. [4] 
    ^abcdeEnglund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, De Micheli A, Hodsoll J, Fusar-Poli P, Strang J, Murray RM, Freeman TP, McGuire P (2023) Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios — Neuropsychopharmacology doi:10.1038/s41386-022-01478-z
  5. [5] 
    ^abcLachenmeier DW, Rehm J (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach — Scientific Reports doi:10.1038/srep08126
  6. [6] 
    ^abcConnor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD (2022) Clinical management of cannabis withdrawal. — Addiction doi:10.1111/add.15743

references

  1. [1] 
    ^abcAndre CM, Hausman JF, Guerriero G (2016) Cannabis sativa: The Plant of the Thousand and One Molecules — Frontiers in Plant Science doi:10.3389/fpls.2016.00019
  2. [2] 
    ^abcHempel B, Xi ZX (2022) Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond — Advances in Pharmacology doi:10.1016/bs.apha.2021.10.006
  3. [3] 
    ^abcRen G, Zhang X, Li Y, Ridout K, Serrano-Serrano ML, Yang Y, Liu A, Ravikanth G, Nawaz MA, Mumtaz AS, Salamin N, Fumagalli L (2021) Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa — Science Advances doi:10.1126/sciadv.abg2286
  4. [4] 
    ^abcdeZuardi AW (2006) History of cannabis as a medicine: a review — Revista Brasileira de Psiquiatria doi:10.1590/s1516-44462006000200015
  5. [5] 
    ^abcdeEnglund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, De Micheli A, Hodsoll J, Fusar-Poli P, Strang J, Murray RM, Freeman TP, McGuire P (2023) Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios — Neuropsychopharmacology doi:10.1038/s41386-022-01478-z
  6. [6] 
    ^abcKaszewska M, Wożniczka K, Sztormowska-Achranowicz K, Mosińska A, Trojan V, Schreiber P, Balog N, Bączek T, Roszkowska A (2025) Perspectives of cannabis-based medicines in a view of pharmacokinetic studies of Δ9-THC and CBD in humans — Biomedicine & Pharmacotherapy doi:10.1016/j.biopha.2025.118673
Last updated Jun 4, 2026